372 related articles for article (PubMed ID: 18090046)
1. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046
[TBL] [Abstract][Full Text] [Related]
2. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
Heil SG; van der Ende ME; Schenk PW; van der Heiden I; Lindemans J; Burger D; van Schaik RH
Ther Drug Monit; 2012 Apr; 34(2):153-9. PubMed ID: 22354160
[TBL] [Abstract][Full Text] [Related]
3. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.
Saitoh A; Fletcher CV; Brundage R; Alvero C; Fenton T; Hsia K; Spector SA
J Acquir Immune Defic Syndr; 2007 Jul; 45(3):280-5. PubMed ID: 17356468
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.
Penzak SR; Kabuye G; Mugyenyi P; Mbamanya F; Natarajan V; Alfaro RM; Kityo C; Formentini E; Masur H
HIV Med; 2007 Mar; 8(2):86-91. PubMed ID: 17352764
[TBL] [Abstract][Full Text] [Related]
5. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
[TBL] [Abstract][Full Text] [Related]
6. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
Chen J; Sun J; Ma Q; Yao Y; Wang Z; Zhang L; Li L; Sun F; Lu H
Ther Drug Monit; 2010 Oct; 32(5):573-8. PubMed ID: 20625352
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.
Habtewold A; Amogne W; Makonnen E; Yimer G; Riedel KD; Ueda N; Worku A; Haefeli WE; Lindquist L; Aderaye G; Burhenne J; Aklillu E
J Antimicrob Chemother; 2011 Oct; 66(10):2350-61. PubMed ID: 21846671
[TBL] [Abstract][Full Text] [Related]
8. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
Wyen C; Hendra H; Vogel M; Hoffmann C; Knechten H; Brockmeyer NH; Bogner JR; Rockstroh J; Esser S; Jaeger H; Harrer T; Mauss S; van Lunzen J; Skoetz N; Jetter A; Groneuer C; Fätkenheuer G; Khoo SH; Egan D; Back DJ; Owen A;
J Antimicrob Chemother; 2008 Apr; 61(4):914-8. PubMed ID: 18281305
[TBL] [Abstract][Full Text] [Related]
10. Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
Uttayamakul S; Likanonsakul S; Manosuthi W; Wichukchinda N; Shioda T; Khusmith S
Southeast Asian J Trop Med Public Health; 2012 Jan; 43(1):78-88. PubMed ID: 23082557
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese.
To KW; Liu ST; Cheung SW; Chan DP; Chan RC; Lee SS
Ther Drug Monit; 2009 Aug; 31(4):527-30. PubMed ID: 19531981
[TBL] [Abstract][Full Text] [Related]
12. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.
Ngaimisi E; Mugusi S; Minzi OM; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Burhenne J; Aklillu E
Clin Pharmacol Ther; 2010 Nov; 88(5):676-84. PubMed ID: 20881953
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial.
Gozalo C; Gérard L; Loiseau P; Morand-Joubert L; Peytavin G; Molina JM; Dellamonica P; Becquemont L; Aboulker JP; Launay O; Verstuyft C;
Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):513-20. PubMed ID: 21824325
[TBL] [Abstract][Full Text] [Related]
14. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.
Tsuchiya K; Gatanaga H; Tachikawa N; Teruya K; Kikuchi Y; Yoshino M; Kuwahara T; Shirasaka T; Kimura S; Oka S
Biochem Biophys Res Commun; 2004 Jul; 319(4):1322-6. PubMed ID: 15194512
[TBL] [Abstract][Full Text] [Related]
15. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine.
Ramachandran G; Ramesh K; Hemanth Kumar AK; Jagan I; Vasantha M; Padmapriyadarsini C; Narendran G; Rajasekaran S; Swaminathan S
J Antimicrob Chemother; 2009 Apr; 63(4):841-3. PubMed ID: 19218571
[No Abstract] [Full Text] [Related]
16. Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
Ngaimisi E; Mugusi S; Minzi O; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Bertilsson L; Burhenne J; Aklillu E
Clin Pharmacol Ther; 2011 Sep; 90(3):406-13. PubMed ID: 21814190
[TBL] [Abstract][Full Text] [Related]
17. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
Gatanaga H; Hayashida T; Tsuchiya K; Yoshino M; Kuwahara T; Tsukada H; Fujimoto K; Sato I; Ueda M; Horiba M; Hamaguchi M; Yamamoto M; Takata N; Kimura A; Koike T; Gejyo F; Matsushita S; Shirasaka T; Kimura S; Oka S
Clin Infect Dis; 2007 Nov; 45(9):1230-7. PubMed ID: 17918089
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
Rotger M; Colombo S; Furrer H; Bleiber G; Buclin T; Lee BL; Keiser O; Biollaz J; Décosterd L; Telenti A;
Pharmacogenet Genomics; 2005 Jan; 15(1):1-5. PubMed ID: 15864119
[TBL] [Abstract][Full Text] [Related]
19. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]